EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing TNBC to Glutaminase Targeting

This study reveals that EZH2 inhibition in triple-negative breast cancer triggers an integrated stress response that drives glutaminolysis to sustain cell survival, thereby identifying glutaminase inhibition as a critical synergistic strategy to overcome resistance and enhance the efficacy of EZH2-targeted therapies.

The Gist

Imagine Triple-Negative Breast Cancer (TNBC) as a highly resilient, stubborn fortress. For a long time, scientists have been trying to break it down using a specific weapon: EZH2 inhibitors. EZH2 is like the "security chief" inside the cancer cells, helping them hide their true nature and survive. The idea was that if you fired the "security chief" (inhibited EZH2), the fortress would crumble.

However, in many cases, the fortress didn't fall. The cancer cells just adapted, found a new way to survive, and kept growing. This paper explains why that happened and, more importantly, how to finally break the fortress down by using a second weapon at the same time.

Here is the story of the discovery, broken down into simple steps:

1. The Failed Attack (The "Security Chief" is Fired)

When scientists used EZH2 inhibitors on the cancer cells, they successfully fired the security chief. The cells' internal "filing system" (chromatin) got messy. Suddenly, the cells started producing a lot of garbage:

• Misfolded proteins: Like trying to build a house with bent bricks; the structure is weak and clogs up the construction site.
• Double-stranded RNA (dsRNA): Imagine the cells accidentally turning on a "siren" or a "fake virus" signal. The cell thinks it's under attack by a virus.

Usually, this garbage pile should kill the cell. But instead, the cancer cells panicked and started a survival mode.

2. The Survival Mode (The "Stress Response" Alarm)

The pile of garbage triggered a massive alarm system inside the cell called the Integrated Stress Response (ISR). Think of this as the cell's "Emergency Response Team" rushing in to clean up the mess.

• The alarm sounded a siren (activating proteins called PKR and PERK).
• This siren woke up a specific manager named ATF4.

ATF4 is the key character. Instead of letting the cell die, ATF4 said, "Okay, we have a mess, but we can fix it! Let's get more supplies!"

3. The New Supply Chain (The "Glutamine" Lifeline)

ATF4 started ordering massive amounts of a specific fuel called Glutamine (an amino acid).

• The cancer cells started eating up glutamine at a frantic rate.
• They used a special machine called Glutaminase (GLS) to process this fuel.
• This fuel did two things:
  1. It powered the cell's engine (mTOR signaling) to keep growing.
  2. It acted as a fire extinguisher, neutralizing the toxic "garbage" (oxidative stress) caused by the initial attack.

The Analogy: Imagine you try to stop a factory by cutting its power (EZH2 inhibition). The factory doesn't shut down; instead, it switches to a backup generator (Glutaminase) that runs on a different fuel (Glutamine) and actually makes the factory run better than before.

4. The Winning Strategy (The "Double Tap")

The researchers realized that while the first weapon (EZH2 inhibitor) made the cancer cells dependent on this backup generator, it didn't kill them. The cells were now addicted to glutamine to survive the stress.

So, they tried a combination therapy:

1. Weapon A: EZH2 inhibitor (Fires the security chief, creates the mess).
2. Weapon B: Glutaminase inhibitor (CB-839) (Destroys the backup generator).

The Result: When they used both weapons together, the cancer cells had no way to clean up the mess and no way to power their engines. The "Emergency Response Team" (ATF4) was overwhelmed, and the cancer cells died.

The Big Picture

• The Problem: EZH2 inhibitors alone are like poking a bear; the bear gets angry (stress response) and becomes stronger.
• The Discovery: The bear's strength comes from a specific food source (Glutamine) it grabs when it gets angry.
• The Solution: If you poke the bear and cut off its food supply at the same time, the bear can't survive.

Why This Matters

This paper suggests that for Triple-Negative Breast Cancer, we shouldn't just use EZH2 inhibitors alone. We should combine them with drugs that block glutamine processing (like Telaglenastat/CB-839). This turns a treatment that barely works into a powerful, life-saving combination that specifically targets the cancer's new weakness.

In short: Don't just break the lock; cut the power to the backup generator too.

Technical Summary

1. Problem Statement

Triple-Negative Breast Cancer (TNBC) is an aggressive subtype with limited treatment options. The epigenetic regulator EZH2 (Enhancer of Zeste Homolog 2) is frequently overexpressed in TNBC and associated with poor prognosis. While EZH2 inhibitors (e.g., tazemetostat) have shown efficacy in hematologic malignancies, their clinical impact in solid tumors like TNBC has been modest.

• The Core Issue: Preclinical models show that while EZH2 inhibition successfully reduces the repressive histone mark H3K27me3, it fails to significantly impair tumor growth. This suggests that TNBC cells activate adaptive compensatory mechanisms that allow them to survive and proliferate despite epigenetic reprogramming.
• The Goal: To identify the molecular mechanisms of this resistance and discover a therapeutic vulnerability that can be targeted in combination with EZH2 inhibitors to improve efficacy.

2. Methodology

The study employed a multi-omics and pharmacological approach using both in vitro cell lines and in vivo patient-derived xenografts (PDXs).

• Models:
  • Cell Lines: MDA-MB-436 and Hs 578T (TNBC cell lines).
  • PDX Models: GCRC1915 and GCRC1939 (TNBC patient-derived xenografts).
  • Genetic Manipulation: CRISPR/Cas9 for EZH2 knockout; siRNA for knockdown of ISR components (PERK, PKR, eIF2α, ATF4) and Glutaminase (GLS).
• Pharmacological Agents:
  • EZH2 Inhibitors: UNC1999 (EZH1/2 inhibitor) and EPZ-6438 (EZH2-selective).
  • Combination Agents: ISRIB (ISR inhibitor), CB-839 (Telaglenastat, GLS inhibitor), BSO (Glutathione synthesis inhibitor), Rapamycin/Torin1 (mTOR inhibitors).
• Key Techniques:
  • Epigenomics: ChIP-seq (H3K27me3, H3K27ac) with Drosophila spike-in normalization to assess chromatin landscape changes.
  • Transcriptomics: RNA-seq to identify differentially expressed genes and Transposable Element (TE) activation.
  • Proteomics & Metabolomics: Immunoblotting, Immunohistochemistry (IHC), LC-MS/MS (targeted metabolomics), and stable isotope tracing ($^{13}$C$_5$-glutamine) to map metabolic flux.
  • Stress Detection: TPE-MI probe for misfolded proteins; J2 antibody immunofluorescence for double-stranded RNA (dsRNA).
  • Functional Assays: Cell viability (Crystal Violet/AlamarBlue), Seahorse analysis (OCR/ECAR), and in vivo tumor growth monitoring.

3. Key Contributions & Findings

A. EZH2 Inhibition Triggers a Specific Stress Response (ISR)

Contrary to the expectation of direct cytotoxicity, EZH2 inhibition in TNBC induces a robust Integrated Stress Response (ISR) rather than cell death.

• Mechanism of Stress: EZH2 inhibition leads to the derepression of Transposable Elements (TEs) (specifically LTRs and LINE-1), resulting in the accumulation of double-stranded RNA (dsRNA). Simultaneously, it causes the accumulation of misfolded proteins (ER stress).
• Signaling Pathway: These stressors activate two kinases:
  1. PKR (activated by dsRNA).
  2. PERK (activated by misfolded proteins).
• Outcome: Both kinases phosphorylate eIF2α, leading to the selective translation and upregulation of the transcription factor ATF4.

B. ATF4 Drives a Metabolic Rewiring Program

The study identifies ATF4 as the central effector that allows TNBC cells to survive EZH2 inhibition.

• Transcriptional Program: ATF4 upregulates genes involved in amino acid transport (e.g., SLC7A5/LAT1, SLC7A11/xCT) and metabolism.
• Metabolic Shift:
  • Increased uptake of glutamine, cystine, and branched-chain amino acids.
  • Enhanced glutaminolysis (conversion of glutamine to glutamate and $\alpha$-ketoglutarate).
  • Activation of the mTORC1 pathway (evidenced by increased p-S6 and p-CAD), which supports protein synthesis and cell growth.
  • Upregulation of antioxidant defenses (glutathione synthesis) to manage oxidative stress.
• Dependency: Depletion of ATF4 abolishes these metabolic changes and sensitizes cells to EZH2 inhibition, confirming its role as a survival factor.

C. Glutaminase (GLS) is a Synthetic Lethal Target

The metabolic adaptation creates a specific dependency on glutamine metabolism.

• GLS Upregulation: EZH2 inhibition significantly increases the expression of Glutaminase (GLS), the enzyme converting glutamine to glutamate. This upregulation is ATF4-dependent.
• Synthetic Lethality:
  • TNBC cells treated with EZH2 inhibitors become highly sensitive to glutamine deprivation.
  • Pharmacological inhibition of GLS using CB-839 (Telaglenastat) combined with EZH2 inhibition (UNC1999) results in profound synergistic cell death in vitro.
  • Mechanistically, GLS inhibition blocks the mTORC1 activation and antioxidant defense mechanisms induced by EZH2 inhibition.

D. In Vivo Efficacy

• Monotherapy: Treatment with UNC1999 alone showed minimal impact on PDX tumor growth despite effective H3K27me3 reduction.
• Combination Therapy: The combination of UNC1999 and CB-839 significantly reduced tumor volume in GCRC1915 PDX models compared to single agents.
• Safety: The combination induced apoptosis (cleaved PARP, cleaved Caspase-3) specifically in tumors without causing toxicity in normal tissues (liver) or affecting mouse body weight.

4. Significance

This study fundamentally reframes the understanding of EZH2 inhibition in solid tumors:

1. Mechanism of Resistance: It reveals that EZH2 inhibition is not inherently cytotoxic in TNBC but rather acts as a stressor that triggers a survival pathway (ISR-ATF4-mTOR).
2. Therapeutic Strategy: It proposes a rational combination therapy strategy. Instead of trying to improve EZH2 inhibitors alone, the study suggests co-targeting the metabolic adaptation (specifically glutaminolysis) that tumors use to survive.
3. Clinical Implication: The findings support the clinical development of combining EZH2 inhibitors with GLS inhibitors (like Telaglenastat) for TNBC patients, potentially overcoming the limited efficacy observed in previous trials. It highlights the importance of targeting stress-induced metabolic vulnerabilities in epigenetic therapy.

Conclusion

The paper demonstrates that EZH2 inhibition in TNBC induces a dsRNA/misfolded protein stress response that activates the ISR-ATF4 axis. This axis reprograms metabolism toward glutamine dependence to sustain mTOR signaling and redox homeostasis. Blocking this adaptation via Glutaminase inhibition sensitizes TNBC to EZH2 blockade, offering a promising combinatorial therapeutic avenue for this aggressive cancer subtype.